
Cullinan Therapeutics' stock pullback offers a buying opportunity ahead of key clinical updates in autoimmune and cancer therapies.
Cullinan Therapeutics (CGEM) recently saw a stock price pullback, which is viewed as a good entry point before upcoming clinical updates scheduled for December 2026. The company is developing targeted treatments for cancer and autoimmune diseases, wi...





